Article
San Francisco-Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma appears feasible in a very select, younger, healthier patient population with slow-growing tumors and human leukocyte antigen (HLA)-matched siblings, said Brian I. Rini, MD. He reported results from a University of Chicago Hospital phase II trial at the 37th annual meeting of the American Society of Clinical Oncology here.